India, Feb. 10 -- Pliant Therapeutics Inc. (PLRX) suffered a major blow on Friday, with its shares tumbling nearly 35% in regular trading and plunging another 58% to $3.27 in after-hours, following an update on its BEACON-IPF trial.
BEACON-IPF is a phase IIb/III trial evaluating the company's lead drug candidate Bexotegrast in patients with idiopathic pulmonary fibrosis.
On Friday (Feb.7, 2025), the company announced that it has voluntarily paused enrollment and dosing in its BEACON-IPF trial following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board (DSMB). Data is being reviewed to understand the reasoning behind the DSMB's recommendation. The company noted that it would maintain the...